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Background: Depression is a leading cause of disability worldwide and, although efficacious treatments are
available, their efficacy is suboptimal and recurrence of symptoms is common. Effective preventive strategies could
reduce disability and the long term social and health complications associated with the disorder, but current
options are limited. Cognitive bias modification (CBM) is a novel, simple, and safe intervention that addresses
attentional and interpretive biases associated with anxiety, dysphoria, and depression. The primary aim of this trial is
to determine if CBM decreases the one-year onset of a major depressive episode among adults with subsyndromal
depression.
Design and methods: This randomised controlled trial will recruit 532 adults with subsyndromal symptoms of
depression living in the Australian community (parallel design, 1:1 allocation ratio). Participants will be free of
clinically significant symptoms of depression and of psychotic disorders, sensory and cognitive impairment, and
risky alcohol use. The CBM intervention will target attentional and interpretive biases associated with depressive
symptoms. The sessions will be delivered via the internet over a period of 52 weeks. The primary outcome of
interest is the onset of a major depressive episode according the DSM-IV-TR criteria over a 12-month period. Sec-
ondary outcomes of interest include change in the severity of depressive symptoms as measured by the Patient
Health Questionnaire (PHQ-9), use of antidepressants or benzodiazepines, and changes in attention and interpretive
biases. The assessment of outcomes will take place 3, 6, 9, and 12 months after randomisation and will occur via
the internet.
Discussion: We propose to test the efficacy of an innovative intervention that is well grounded in theory and for
which increasing empirical evidence for an effect on mood is available. The intervention is simple, inexpensive, easy
to access, and could be easily rolled out into practice if our findings confirm a role for CBM in the prevention of
depression.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12613001334796. Date: 5th December
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Depression affects people of all ages and has an esti-
mated lifetime prevalence of 27% [1]. The personal and
social costs associated with depression are difficult to
measure, but currently available evidence indicates that
direct financial loss is in the order of A$100,000 over
the lifetime of a person and approximately A$15 billion
per annum for the Australian society [2]. People with
depression have more unplanned admissions to general
hospitals and longer length of stay than people without
depression and, once admitted, they have nearly twice
the risk of death as those without past history of depres-
sion [3]. In other words, depression is a common, costly,
and disabling disorder that reduces life expectancy. Con-
sequently, the successful prevention of depression would
lead to important health and socioeconomic benefits.
Currently available strategies to prevent depression: who
should we target?
Various approaches have been used with the aim of re-
ducing the prevalence of depression in the community.
Some have focused on improving the identification of
people with depression, while others have sought to in-
crease the efficacy and effectiveness of existing manage-
ment strategies. A meta-analysis of 16 randomised trials
has shown that the systematic use of screening instru-
ments or case-finding procedures increases the recogni-
tion of depression by a modest 27%, and this has no
effect on the adoption of treatments or the clinical out-
come of patients [4]. Similarly, the evidence to support
the value of educational interventions targeting medical
practitioners to enhance the treatment of depression is
not robust [5]. In view of these limitations, increasing
emphasis has been placed on the potential value of strat-
egies that instead seek to reduce the prevalence of de-
pression through prevention.
Recent pragmatic approaches to prevent depression
have focused on the targeted delivery of programs to
people with symptoms of depression that do not reach
threshold for the diagnosis of a disorder, an approach
known as indicated prevention [6]. The rationale, in this
case, is that people with ‘subsyndromal depression’ are at
greater risk of developing a full-blown major depressive
episode than people who are free of depressive symp-
toms, and so may benefit most from interventions de-
signed to reduce risk. Data from the PROSPECT trial,
which recruited older adults from primary care practices
in New York, Philadelphia, and Pittsburgh, showed that
10.4% of people with subsyndromal depression devel-
oped a major depressive episode within one year com-
pared with 0.8% of participants who were free of these
symptoms [7]. The PIKO study is a good illustration of a
trial of indicated prevention [8], where the investigators
recruited 170 adults aged 75 years or over who scored16 or more on the Center for Epidemiologic Studies De-
pression Scale (CES-D) but did not fulfil DSM-IV cri-
teria for a depressive or anxiety disorder at the time of
assessment or during the preceding 12 months. They
implemented a stepped care intervention that consisted
of ‘watchful waiting’ for the first 3 months, then poten-
tially progressing to bibliotherapy (if subsequent CES-D
≥16), followed by problem solving therapy and, lastly,
treatment with antidepressant medications. The relative
risk of developing a depressive or anxiety disorder
among people receiving the intervention compared with
usual care was 0.49 (95% confidence interval = 0.24–
0.98) by the end of 12 months. During this period, 4 par-
ticipants met criteria for a depressive disorder, 3 for an
anxiety disorder, and 2 for mixed anxiety and depression
in the intervention group compared with 10 cases of de-
pressive disorder, 5 of anxiety, and 5 mixed states in the
usual care group. However, there was no statistically sig-
nificant difference between the groups when the out-
come of the study was limited to depression. In addition,
dropout was higher in the intervention than in the usual
care group (24/86 vs. 8/84), suggesting problems with
the acceptability of the intervention by participants.
The value of indicated prevention approaches in redu-
cing the risk of major depression is not restricted to
older adults. A recent review of studies across the life-
span reported data on 33 trials of indicated or selective
prevention (for example, post-stroke patients), most of
which used cognitive behavioural therapy (CBT) or
problem solving as the active intervention [9]. There
was an overall benefit of the interventions (about 25%
relative risk reduction of clinically significant depres-
sion), although the non-independence of some studies
was not taken into account in the analyses (i.e., trials
with more than one intervention group were treated as
separate studies).
In summary, existing evidence indicates that adults
with subsyndromal symptoms of depression have sub-
stantially greater risk of developing a major depressive
episode over the subsequent year compared with people
free of these symptoms. Averting the onset of major de-
pression in people at risk seems feasible, but clearly ef-
fective preventive strategies are yet to be established.
Biased thinking patterns are both markers and predictors
of depression
The theoretical framework underpinning CBT posits
that depressed mood is produced by a set of biased
thinking processes that commonly involve preferential
attention to negative aspects of experience and an in-
flated tendency to attribute negative interpretations to
ambiguous events. Such a bias in the processing of infor-
mation initiates the cycle of negative thinking, dysfunc-
tional beliefs, withdrawal, and psychomotor changes that
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negative thoughts about the self, others, and the future,
by teaching patients to rationally appraise these thoughts
and to generate more accurate and functional alterna-
tives. Effective shifts of dysfunctional biased beliefs have
been associated with a robust response to treatment and
a decreased risk of relapse of symptoms [11]. Import-
antly, such a pattern of biased beliefs and negative think-
ing are strong predictors of the development of future
depression. For example, children with no history of de-
pression, but known to be at high risk on the basis of a
parent’s history, exhibit the same biased pattern of nega-
tive thinking and beliefs [12]. In a longitudinal study car-
ried out over a 2.5 year period with 347 college students,
those who initially displayed negatively biased thinking
were 3 to 7 times as likely as controls to develop an epi-
sode of major depression [13]. These findings indicate
that if the mechanisms that give rise to negatively biased
thoughts and beliefs could be identified and effectively
targeted, this could protect against the future develop-
ment of depression in high-risk individuals.
Emerging empirical and clinical findings are consistent
with the hypothesis that selective biases in attention and
interpretation, operating to favour the processing of
emotionally negative information, represent the psycho-
logical basis of disordered mood [14-16]. For example,
adults with mood disorders shown a series of faces on a
computer screen selectively direct their attention to sad
faces, but show no such a bias when presented with
angry or happy faces [17]. Moreover, people without a
history of depression, but known to be at heightened risk
(e.g., daughters of depressed mothers), display this same
attentional bias to negative information [18]. Such find-
ings are consistent with the idea that attentional bias
precedes and potentially contributes to the precipitation
of depressive episodes. In addition, when faced with am-
biguity, people with depressed mood favour negative in-
terpretations of stimuli. For example, when presented
the ambiguous cue word ‘GROWTH’, people with low
mood are faster to then complete fragments of target
words semantically related to the negative rather than
the non-negative meanings of the ambiguous cue:
C_NC_ER and GR_AT_R (cancer and greater) [19].
Once again, such bias has been found to characterise
people with no history of depression known to be at
high risk of developing this disorder [20]. These results
confirm that attentional and interpretation biases are
not only associated with concurrent disturbances of
mood, but also represent risk factors for future mood
disorders. They also invite the question: are these biases
amenable to change?Cognitive bias modification (CBM) procedures are
effective at extinguishing selective processing bias
MacLeod and colleagues introduced the most widely
used approach worldwide to modify attentional bias
[21]. The procedure exposes participants to pairs of
words or images on a computer screen for 500 ms, with
each pair including one emotionally negative and one
neutral item. Immediately after the words/images dis-
appear, a single small visual probe (vertical or horizontal
white line) is presented in the same spatial position
where one of the original stimuli had been displayed.
Participants are required to indicate, as quickly as pos-
sible, the orientation of this probe (horizontal or verti-
cal), and their speed to accurately do so is recorded over
dozens of trials. People who display an attentional bias
to the more negative information are faster to make dis-
crimination judgments for probes that appear in the
same area as the negative stimuli, compared to probes in
the area of the neutral stimuli [21]. Cognitive bias modi-
fication for attention (CBM-A) delivers hundreds to
thousands of trials in which all probes are consistently
presented where the neutral rather than the negative
stimuli had just appeared, in order to encourage devel-
opment of an attentional avoidance of negative response
to information. A control condition presents probes with
equal frequency to each of these two areas. In CBM de-
signed to reduce negative interpretations (CBM-I), par-
ticipants are exposed to trials that present ambiguous
information, followed by a target word fragment that
must be completed in a semantically consistent manner.
CBM-I delivers hundreds of trials in which target frag-
ments can yield only words consistent with non-negative
interpretations of the ambiguity, thus encouraging the
tendency to interpret ambiguity in a benign manner.
Hence, the ambiguous text “When you chat to people at
a party they are soon chuckling, because you are so”, will
be followed by the fragment W_T_Y (yielding WITTY).
A control condition employs fragments that equally
often yield words consistent with negative (e.g., S_L_Y)
or non-negative interpretation of the ambiguity.
CBM reduces anxiety and improves mood
Emerging research shows that CBM-A attenuates anx-
iety reactions to stressful life events [22], reduces recur-
rent negative thought intrusions in chronic worriers
[23], decreases avoidant behaviours [24], and mitigates
the intensity of depressive symptoms among dysphoric
patients over a 2-week period [25]. However, negative
findings have also been reported, with an internet-based
intervention failing to improve symptoms associated
with social anxiety over a period of 4 weeks [26]. A re-
cent, as yet unpublished, meta-analysis concluded that
CBM is associated with small beneficial effects on symp-
toms of anxiety and depression, but that the quality and
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sonal communication). In addition, CBM-A normalises
the cortisol awakening response that is characteristic of
depressive disorders [27]. The results of CBM-I inter-
ventions indicate that they too reduce negative emotions
following stress [28,29]. There is preliminary evidence
that combining CBM-A and CBM-I may be useful in re-
ducing existing emotional dysfunction. For example,
Beard and colleagues randomly assigned 32 adults with
social anxiety disorder to 16 sessions of combined CBM
over a period of 8 weeks: participants exposed to this
combined CBM experienced a significantly greater re-
duction of anxiety symptoms than controls [30]. How-
ever, it remains to be established if this combination of
CBM-A and CBM-I can reduce the risk of a novel epi-
sode of major depression when delivered to participants
known to be at increased risk for the disorder.
The primary aim of this trial is to determine if CBM
designed to attenuate negative attentional and interpret-
ive biases decreases the one-year onset of major depres-
sive episodes among adults with subsyndromal
symptoms of depression. The primary hypothesis of this
trial is that a lower proportion of participants assigned
active compared with control CBM will develop a de-
pressive episode over a period of one year. The study
will also test whether, compared with the control group,
CBM reduces the severity of depressive symptoms and
lowers the frequency of antidepressant and benzodiazep-




The COgnitive bias modification to Prevent dEpression
(COPE) study is a randomised, double-blind, parallel,
controlled trial of CBM delivered over the internet. The
allocation ratio will be 1:1.
Ethics
The activities and procedures of this trial follow the
principles outlined by the Declaration of Helsinki. The
Human Research Ethics Committee of the Department
of Health of Western Australia has approved the re-
search protocol (#2013/57) and all participants will pro-
vide written informed consent.
Participants and setting
We will recruit 532 adults with subsyndromal symptoms
of depression living in the Western Australian commu-
nity. They will need to fulfil the following criteria for
participation:
– Patient Health Questionnaire (PHQ-9) total score
between 5 and 14, inclusive (described below)– Age ≥45 years (to avoid including people with
bipolar disorder) [31]
– Fluent in written and spoken English
– Have access to a computer with internet connection
– No current or past DSM-IV-TR diagnosis of major
depressive episode (Structured Clinical Interview for
DSM Disorders (SCID-I) – see below)
– No current or past diagnosis of schizophrenia,
schizoaffective disorder, or bipolar disorder
– No past history of stroke or of neurodegenerative
diseases (e.g., Parkinson’s disease)
– Free of diseases likely to undermine ongoing
participation in the study for 12 months (e.g.,
metastatic cancer)
– No evidence of alcohol abuse or dependence
(AUDIT ≥15 – see below)
– No evidence of cognitive impairment (Telephone
Interview for Cognitive Status (TICSm) <27 – see
below)
– No evidence of active suicidal intent
– No evidence of visual impairment that might
compromise ability to read or use the computer
– Registered with a general practitioner
We will obtain a random extraction of 20,000 names
of adults aged 45 years or over living in the community
from the Australian Electoral Commission (enrolment to
vote is compulsory in Australia). They will receive, by
post, information about the study together with a
screening questionnaire designed to ascertain eligibility.
The screening questionnaire will ascertain the following
information: personal contact details, contact details of
GP, gender, date of birth, date of assessment, place of
birth, language spoken at home, self-perceived fluency in
English, regular access and use of a computer and the
internet, past diagnosis of neurological disorders (stroke,
Parkinson’s disease, Alzheimer’s disease), current history
of metastatic cancer, past diagnosis of depression, partial
or total blindness, and list of all medications that the
volunteer is currently using. The questionnaire will also
include the following scales:
– PHQ-9: the PHQ-9 is a widely used and well-
accepted screening instrument for depression
[32,33]. The scale consists of 9 questions about how
often the respondent has been bothered by depres-
sive symptoms during the past 2 weeks, and each
item can be scored 0 (not at all), 1 (several days), 2
(a week or more) or 3 (nearly every day). The 9
items are: (a) decreased interest or pleasure, (b) low
mood, (c) sleep disturbance, (d) lack of energy, (e)
disturbed appetite, (f ) feelings of failure or guilt, (g)
poor concentration, (h) psychomotor disturbance,
and (i) suicidal thoughts. The PHQ-9 is a simple
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minutes to complete. Scores between 5 and 14, in-
clusive, indicate mild or subsyndromal depression.
– Alcohol Use Disorders Identification Test (AUDIT):
this 10-item questionnaire has been designed as a
screening instrument for risk drinking. The scale
takes 2 minutes to complete, and scores ≥15 indicate
hazardous/harmful alcohol use or dependency [34].
Returned screening questionnaires will be immediately
scanned and volunteers deemed potentially eligible will
be contacted within 2 weeks to organise a telephone
interview for the assessment of cognitive function
(TICSm) [35] and, for those free of cognitive impair-
ment, an assessment of current and past mental state
with the SCID-I, which is a structured clinical interview
for axis I diagnoses that can be administered by trained
research staff over the telephone [36]. It provides reliable
and valid information to establish the diagnosis of major
depressive episode (recurrent or single episode) accord-
ing to DSM-IV-TR criteria [37] (which is consistent with
DSM-5 criteria). Participants with a current major de-
pressive episode will be excluded from further participa-
tion. Volunteers deemed eligible will be given a user
name and password to access the CBM website. When
they first login, their username will be linked to a num-
ber from a random list of study numbers, which will be
randomly assigned to either the intervention or control
CBM. Additional lists will be requested from the Austra-
lian Electoral Commission until the total number of par-
ticipants enrolled in the study reaches the required
number of 532 people.
Intervention
Eligible participants will be randomly allocated to one of
two treatment arms: control or active CBM (parallel de-
sign, 1:1 allocation). CBM sessions will be delivered over
a period of 52 weeks (1 year) according to the following
schedule:
– three times per week for the first 4 weeks
– twice weekly for the next 4 weeks (up to week 8)
– once weekly for the next 18 weeks (up to week 26)
– once every other week for the next 12 weeks (up to
week 38)
– once per month for the remainder of the follow-up
period (up to week 52)
This delivery schedule is designed to achieve rapid bias
modification through initially intensive training, while
also encouraging maintenance of the resulting cognitive
change by sustained exposure to CBM across an ex-
tended period and by phasing out rather than abruptly
terminating the intervention. Each CBM session will last20 minutes (10 minutes attention, 10 minutes interpret-
ation), and will be accessed through a password-
protected website. On each session, participants will be
presented with a pair of emotionally-toned facial images
(sad vs. neutral or happy) for 500 ms, which will then be
replaced by a small white probe (vertical or horizontal
line), appearing in the screen position previously occu-
pied by one of these stimuli. Participants will be
instructed to use their keyboard to indicate the orienta-
tion of this probe as quickly as possible (‘V’ for vertical,
‘H’ for horizontal). The probe will then disappear and
will be replaced, after 1 second, by another stimulus pair
that will commence the next trial. The time to discrim-
inate probe identity will be recorded automatically. In
the active CBM condition, all probes will appear in the
opposite screen area from that of the negative stimulus,
while in the control CBM condition probes will appear
equally often in the area of the negative and non-
negative stimuli.
The second half of each 20-minute session will deliver
CBM-I using single words and short textual scenarios as
ambiguous stimuli. On each trial, this ambiguous stimu-
lus will first be presented (e.g., word ‘HIT’), followed,
500 ms later, by a fragment of a word that is semantic-
ally consistent with one or other meaning of the preced-
ing ambiguity (e.g., ‘S_CCESS’ or ‘P_NCH’). Participants
will be instructed to use their keyboard to complete this
fragment to yield a word consistent with the meaning of
the initial word or sentence. The time to solve the word
fragments will be recorded automatically. In the active
CBM condition all fragments will yield only words con-
sistent with non-negative interpretations of the preced-
ing ambiguity, while in the control CBM condition
fragments will equally often yield words consistent with
the negative and non-negative interpretation of this
ambiguity.
Outcomes and study measures
The primary outcome of interest of this study is the on-
set of a major depressive episode over a 12-month
period, which we will assess with the SCID-I 3, 6, 9, and
12 months after randomisation. The use of the SCID-I
will allow for the ascertainment of depressive episodes
that may have occurred between assessments, and will
also enable us to assess clinically significant symptoms
of anxiety that may have arisen in isolation or comorbid
with depression. This assessment will take place via a
telephone interview.
Secondary outcomes of interest include: i) proportion
of people experiencing the onset of clinically significant
symptoms of depression, as established by a PHQ-9 total
score of 15 or greater, ii) change in the severity of de-
pressive symptoms as measured by the PHQ-9, iii) the
proportion of people using antidepressants or
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pretive biases. The assessment of these secondary out-
comes will take place 3, 6, 9, and 12 months after
randomisation and will occur via the internet (i.e., elec-
tronic questionnaire and assessment of cognitive bias
using the same procedures described for the
intervention).
Attentional bias will be measured as the difference, in
ms, to respond to the probes appearing in location asso-
ciated with the negative compared with the emotionally
non-negative faces. Similarly, negative interpretive bias
will be operationalised as the relative speeding to
complete the words associated with the negative com-
pared with the non-negative ambiguous words/contexts.
Table 1 shows COPE’s assessment schedule.
None of the activities or procedures of COPE are haz-
ardous. Adherence to the study protocol will be recoded
automatically through monitoring of scheduled activities:
70 to 100% compliant, 50 to 70% partly compliant, <50%
non-compliant. Participants who drop out from the
study will be contacted by telephone to ascertain the
reasons for their discontinuation, which will be recorded
and later reported.
Data entry, coding, security, and storage
The contact details of consenting participants will be
kept in an Excel spreadsheet that will also contain a
unique identifier number. This unique identifier will be
generated by computer and will be used to identify par-
ticipants in the study working database. Data collected
via the postal questionnaire and interview with the SCID
will be entered manually into an Excel spreadsheet. Data
collected via the internet will be recorded automatically
and later transported to an Excel spreadsheet, which will
then be imported into Stata for statistical analysis (Stata-
Corp, version 13.1). Postal and SCID data will be kept in
a locked filing cabinet at the Western Australia Centre
for Health & Ageing. Electronic data will be kept in a se-
cure server of the University of Western Australia. Study
data will be kept for a minimum of 7 years following
completion of the trial.Table 1 List and timeline of assessments for the Healthy Tran
Assessments: Scree
Sociodemographic/clinical information (postal questionnaire) YES
AUDIT (postal questionnaire) YES
TICSm (telephone) YES
SCID (telephone) YES
PHQ-9 (postal for screening; internet for all other endpoints)* YES
Attentional and interpretive bias –
*Includes an additional 6-week assessment. AUDIT, Alcohol use disorders identificat
for DSM Disorders; TICSm, Telephone interview for cognitive status.Sample size
About 10% of adults with subsyndromal symptoms of
depression develop a major depressive episode over the
subsequent 12 months [7]. We anticipate that CBM will
be associated with an absolute risk reduction of major
depression of 6% over this period (i.e., annual incidence
of 4% compared with 0.8% for people free of subsyndro-
mal depression – still high, but lower than controls with
subsyndromal depression). This would require that 444
(222 per group) participants provide valid data to ascer-
tain this endpoint of the study (power of 80% and two-
tailed alpha of 5%). We further anticipate that as many
as 20% of our volunteers may be lost during follow-up,
which would require that 532 participants enter the
study (266 per group). The number need to treat for one
to benefit from CBM would be 17. If the PHQ-9 scores
of participants declines, on average, 0.5 points for con-
trols (SD = 4) and 3 points for active CBM participants
(SD = 1.5), then a study of this size would have 97%
power to declare such difference between the groups as
statistically significant (two-sided alpha = 5%). The
changes in response bias (measured in ms) are expected
to be associated with a minimum effect size of 0.4
(Cohen’s d) [22], which would require about 50 trials per
participant (within group comparison). As each CBM
session includes 180 trials for attention (faces) and 180
trials for interpretive bias (words), the study will have
ample power to investigate this outcome.
Two of our previous community-based trials showed
that 19.8% of mature adults have subsyndromal depres-
sive symptoms [5,38], indicating that we will need to
screen 2,687 community-dwelling people to accrue 532
eligible cases. Response to our previous invitations has
been of the order of 15 to 20%. If we assume that 15% of
those invited will consent to screening, we will need to
invite 18,000 people, to screen 2,687 participants, and
recruit 532 into the trial. We will seek to approach
20,000 people.sition Trial
Month
ning 0 3 6 9 12
– – – – –
– – – – –
– – – – –
– YES YES YES YES
– YES YES YES YES
YES YES YES YES YES
ion test; PHQ-9, Patient Health Questionnaire; SCID, Structured Clinical Interview
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Participants will be assigned to one of the two treatment
arms of the study according to lists of random numbers
generated by computer in random permuted blocks of 8
to 20. The lists will be generated and maintained by the
Centre for Software Practice of the University of West-
ern Australia, which will have no direct contact with
participants. Neither staff nor participants will be aware
of group assignment. Participants will be instructed that
the focus of their activity is to identify the orientation of
the probe (vertical or horizontal) and the missing letter
of the word fragment as quickly as possible. In this re-
spect, control and active CBM tasks are indistinguish-
able. Research staff involved in the collection of
endpoints will be directed not to discuss with partici-
pants any aspects of the intervention. Unblinding will
only occur once the final endpoint of interest is collected
from the last participant in the trial.
All logins and logouts will be recorded automatically,
so that the trial will have an objective measure of the ad-
herence of participants to the scheduled activities. In
order to optimise the completion of scheduled activities
of the study, participants will receive an automated text
message and/or email (as per stated preference) alerting
them to upcoming study activities for the week ahead
and encouraging them to complete the relevant tasks.
Once an activity is completed, participants will receive a
text/email thanking them and outlining the next activity
in their schedule.
Statistical methods
We will use means and standard deviations to describe
continuous variables with normal distribution, medians,
and inter-quartile ranges for ranked variables, and fre-
quency tables for categorical variables. We will evaluate
the primary endpoint of the study by considering the
proportion of participants showing evidence of depres-
sion during follow-up. Our approach to the analysis will
be intention-to-treat and will use panel data accrued at
different time points. We will use the command ‘xtlogit’
of the statistical package Stata 13.1 to complete these
analyses, and models will be adjusted for imbalances that
might be present at baseline. This approach to the ana-
lysis will also allow us to investigate interactions be-
tween treatment group and time. Similarly, we will use
multilevel mixed models to analyse changes in PHQ-9
scores and in attentional and interpretive biases from
baseline to month 12. We will investigate the interaction
between group and time effects (statistical adjustments
will be made, if necessary). This analysis will also be
intention-to-treat. This approach to the analysis of the
data (panel; repeated measures) increases study power
and lessens the impact of missing data. All probability
tests will be two-tailed (P <0.05).Discussion
Depression is a leading cause of disability and health ex-
penditure in Australia and worldwide. Attempts to de-
velop strategies to prevent depression have focused
predominantly on people at high risk, such as those with
subsyndromal symptoms, although results have been
mixed and costs high. COPE will test the efficacy of a
highly innovative intervention that is well grounded in
theory and for which increasing empirical evidence for
an effect on mood is available. We used best available
evidence to estimate the number of people with subsyn-
dromal symptoms of depression likely to develop a de-
pressive episode over a 1-year period [7], and a schedule
of activities designed to shift existing biases during the
first few weeks of treatment and progressively less fre-
quent booster sessions designed to sustain these
changes. The intervention targets both attentional and
interpretative biases, as this seems to enhance treatment
response [30]. This intervention is simple, inexpensive,
easy to access via the internet, and could be easily rolled
out into practice if our findings confirm a role for CBM
in the prevention of depression. Our strategy to recruit
participants has been used successfully before and will
give us the flexibility to expand recruitment in a timely
manner, if necessary. All study procedures have been
piloted: they are working as planned and have been well
accepted by users. We anticipate that we will need three
years to complete the collection of all outcomes of this
study.
Trial status
The COPE trial is currently recruiting participants.
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